Log in

Relevant bibliographies by topics / Advanced prostatic carcinoma / Journal articles

To see the other types of publications on this topic, follow the link: Advanced prostatic carcinoma.

Journal articles on the topic 'Advanced prostatic carcinoma'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Advanced prostatic carcinoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kozlowski, James M., William J. Ellis, and John T. Grayhack. "Advanced Prostatic Carcinoma." Urologic Clinics of North America 18, no. 1 (1991): 15–24. http://dx.doi.org/10.1016/s0094-0143(21)01389-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rasool, Mumtaz, Shafiq Ahmad Iqbal, Mudassar Saeed Pansota, Shafqat Ali Tabassum, and Iftikhar Ahmad. "PROSTATIC CARCINOMA." Professional Medical Journal 22, no. 06 (2015): 710–14. http://dx.doi.org/10.29309/tpmj/2015.22.06.1236.

Full text

Abstract:

Introduction: During the past many years the availability of serum PSAas a screening marker, has encouraged its use to diagnose both prostatic cancer and itsrecurrence. Patients with high S/PSA are at increased risk of advanced carcinoma prostate andscreening at an earlier stage would help to manage it accordingly. The aim of this study wasto determine association between serum prostatic specific antigen (PSA) levels and Gleasongrade in prostatic carcinoma patients. Study Design: Descriptive, case series study. Setting:Department of Urology & Renal Transplantation in collaboration with Ins

APA, Harvard, Vancouver, ISO, and other styles

3

HARNETT, P. R., D. RAGHAVAN, I. CATERSON, et al. "Aminoglutethimide in Advanced Prostatic Carcinoma." British Journal of Urology 59, no. 4 (1987): 323–27. http://dx.doi.org/10.1111/j.1464-410x.1987.tb04641.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Apple, J. S., D. F. Paulson, C. Baber, and C. E. Putman. "Advanced prostatic carcinoma: pulmonary manifestations." Radiology 154, no. 3 (1985): 601–4. http://dx.doi.org/10.1148/radiology.154.3.2578678.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kuban, Deborah A., Paul F. Schellhammer, and Anas M. El-Mahdi. "Hemibody Irradiation in Advanced Prostatic Carcinoma." Urologic Clinics of North America 18, no. 1 (1991): 131–37. http://dx.doi.org/10.1016/s0094-0143(21)01400-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Biers, Suzanne M., Mark E. Sullivan, Ian S. D. Roberts, and Jeremy G. Noble. "Thrombotic microangiopathy in advanced prostatic carcinoma." Urology 63, no. 2 (2004): 380–82. http://dx.doi.org/10.1016/j.urology.2003.09.069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ruff, P., D. P. Derman, A. Weaving, and W. R. Bezwoda. "Systemic treatment of advanced prostatic carcinoma." Journal of Steroid Biochemistry 28 (January 1987): 82. http://dx.doi.org/10.1016/0022-4731(87)91339-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Seftel, Allen D., J. Patrick Spirnak, and Martin I. Resnick. "Hormonal Therapy for Advanced Prostatic Carcinoma." Journal of Surgical Oncology 42, S1 (1989): 14–20. http://dx.doi.org/10.1002/jso.2930420505.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Goktas, S., A. Ziada, and ED Crawford. "Combined androgen blockade for advanced prostatic carcinoma." Prostate Cancer and Prostatic Diseases 2, no. 4 (1999): 172–79. http://dx.doi.org/10.1038/sj.pcan.4500323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kayigil, Ö., Ö. Atahan, and A. Metin. "Cyproterone acetate monotherapy in advanced prostatic carcinoma." International Urology and Nephrology 29, no. 2 (1997): 213–20. http://dx.doi.org/10.1007/bf02551344.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Demianets, Roksolana, Dong Ren, Roozbeh Houshyar, Giovanna A. Giannico, and Cary Johnson. "Primary Adenosquamous Carcinoma of the Prostate." Diagnostics 14, no. 6 (2024): 645. http://dx.doi.org/10.3390/diagnostics14060645.

Full text

Abstract:

Prostate cancer accounts for 29% of malignant diagnoses among men in the United States and is the second leading cause of death from cancer. Effective screening methods and improved treatment have decreased the mortality rate significantly. This decreased mortality rate, however, does not apply to all histologic variants. Adenosquamous carcinoma of the prostate is an extremely aggressive neoplasm with no current known curative therapy. It is often diagnosed after chemotherapy, radiation, or androgen deprivation therapy for traditional prostatic adenocarcinomas. Primary carcinomas of the prosta

APA, Harvard, Vancouver, ISO, and other styles

12

Cormio, Luigi, Ilkka Perttilä, Osmo Saarinen, Esko Tierala, Stig Nordling, and Mirja Ruutu. "Spontaneous Perforation of the Rectum by Carcinoma of the Prostate. Case Report." Tumori Journal 79, no. 4 (1993): 280–82. http://dx.doi.org/10.1177/030089169307900412.

Full text

Abstract:

A case of spontaneous perforation of the rectum by a locally advanced prostatic carcinoma is described. The mechanisms of rectal involvement by prostatic carcinoma are discussed, focusing attention on the difficulties in differential diagnosis with primary carcinoma of the rectum.

APA, Harvard, Vancouver, ISO, and other styles

13

Krušlin, Božo, Lucija Škara, Tonći Vodopić, et al. "Genetics of Prostate Carcinoma." Acta Medica Academica 50, no. 1 (2021): 71. http://dx.doi.org/10.5644/ama2006-124.327.

Full text

Abstract:

<p>The aim of this review is to provide a brief overview of some current approaches regarding diagnostics, pathologic features, treatment, and genetics of prostate carcinoma (PCa). Prostate carcinoma is the most common visceral tumor and the second most common cancer-related cause of death in males. Clinical outcomes for patients with localized prostate cancer are excellent, but despite advances in prostate cancer treatments, castrate-resistant prostate cancer and metastatic prostate cancer patients have a poor prognosis. Advanced large-scale genomic studies revealed a large number of ge

APA, Harvard, Vancouver, ISO, and other styles

14

Pummer, K., M. Lehnert, and H. L. Seewann. "Chemohormonal and Immunohormonal Approaches in Advanced Prostatic Carcinoma." European Urology 24, no. 2 (1993): 81–86. http://dx.doi.org/10.1159/000474397.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

KYNASTON, H. G., C. W. KEEN, and P. N. MATTHEWS. "Radiotherapy for Palliation of Locally Advanced Prostatic Carcinoma." British Journal of Urology 66, no. 5 (1990): 515–17. http://dx.doi.org/10.1111/j.1464-410x.1990.tb15000.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Mathews, Mary, Abhishek Kumar, Nelly Awkar, Deepak Dhaliwal, and Michael Maroules. "Hypercalcemia in Advanced Prostatic Carcinoma: A Rare Event." American Journal of Medical Case Reports 3, no. 3 (2015): 64–65. http://dx.doi.org/10.12691/ajmcr-3-3-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Presant, Cary A., Mark S. Soloway, Sol S. Klioze, et al. "Buserelin as primary therapy in advanced prostatic carcinoma." Cancer 56, no. 10 (1985): 2416–19. http://dx.doi.org/10.1002/1097-0142(19851115)56:10<2416::aid-cncr2820561013>3.0.co;2-#.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Soloway, Mark S., and Haim Matzkin. "Antiandrogenic agents as monotherapy in advanced prostatic carcinoma." Cancer 71, S3 (1993): 1083–88. http://dx.doi.org/10.1002/1097-0142(19930201)71:3+<1083::aid-cncr2820711430>3.0.co;2-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Fandella, A., P. Checchin, L. Maccatrozzo, et al. "Cervical or trigonal transurethral resection in local advanced carcinoma of the prostate. Our experience." Urologia Journal 61, no. 2 (1994): 142–47. http://dx.doi.org/10.1177/039156039406100210.

Full text

Abstract:

Gli Autori riportano l'esperienza riguardo alla resezione endoscopica prostatica o trigonale (TUR) nei pazienti con neoplasia prostatica non suscettibile di soluzione radicale e non rispondente localmente alla terapia ormonale, con sintomatologia ostruttiva o con estensione trigonale ed infiltrazione degli osti ureterali (fino all'insufficenza renale). Tale metodica viene ritenuta una valida alternativa ad una derivazione urinaria mediante cateterismo o nefrostomia, sotto il profilo di una migliore qualità di vita. Vengono considerati 63 pazienti, su 72 trattati in 6 anni, con follow-up medio

APA, Harvard, Vancouver, ISO, and other styles

20

Lara, Primo N., Andreas M. Heilmann, Julia A. Elvin, et al. "TMPRSS2-ERG Fusions Unexpectedly Identified in Men Initially Diagnosed With Nonprostatic Malignancies." JCO Precision Oncology, no. 1 (November 2017): 1–6. http://dx.doi.org/10.1200/po.17.00065.

Full text

Abstract:

Purpose TMPRSS2-ERG gene fusions are frequently found in prostate cancer and are pathognomonic for prostatic origin. In a series of cancer cases assayed with comprehensive genomic profiling (CGP) in the course of clinical care, we reviewed the frequency of TMPRSS2-ERG fusions in patient tumors of various histologic subtypes. Methods Frequency of TMPRSS2-ERG fusions was determined in CGPs from 64,263 cancer cases submitted to Foundation Medicine to assess genomic alterations suggesting benefit from targeted therapy. Genomic results are presented from an index case of prostate cancer that underw

APA, Harvard, Vancouver, ISO, and other styles

21

Lauffer, David Cédric, Florian Johann Werner Lang, Marc Kueng, and Abdelkarim Said Allal. "Unusual Case of Laryngeal Squamous Cell Carcinoma with Cervical Metastasis of a Prostatic Adenocarcinoma: A Case Report." Case Reports in Oncology 10, no. 1 (2017): 316–20. http://dx.doi.org/10.1159/000470831.

Full text

Abstract:

Brain and Head and neck metastases are rare in prostatic carcinoma patients. In this report we present a very uncommon case of the concomitant occurrence of a prostatic adenocarcinoma with neck metastases and an advanced laryngeal squamous cell carcinoma without neck metastases. The presence of cervical lymph node prostate adenocarcinoma metastasis concomitantly with a laryngeal squamous cell carcinoma is at least intriguing and may remind us of a rare event called “collision tumors”. In this case we had the metastatization of 1 carcinoma to the site of the drainage of another carcinoma, but w

APA, Harvard, Vancouver, ISO, and other styles

22

Jindal, P. K., D. Hota, K. V. R. Prasad, R. Nijhawan, and S. Vaidyanathan. "Advanced Prostatic Carcinoma in a 19-Year-Old Male." Urologia Internationalis 52, no. 4 (1994): 225–27. http://dx.doi.org/10.1159/000282615.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Borgmann, V., H. Al-Abadi, and R. Nagel. "Treatment of Locally Advanced Prostatic Carcinoma With LHRH Analogues." American Journal of Clinical Oncology 11, Supplement 1 (1988): S29. http://dx.doi.org/10.1097/00000421-198812001-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ferro, M. A., D. Gillatt, M. O. Symes, and P. J. B. Smith. "High-dose intravenous estrogen therapy in advanced prostatic carcinoma." Urology 34, no. 3 (1989): 134–38. http://dx.doi.org/10.1016/0090-4295(89)90248-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Jain, A., M. Ablett, and P. Wardrop. "Vanishing tumour of the internal auditory meatus." Journal of Laryngology & Otology 123, no. 5 (2008): 563–65. http://dx.doi.org/10.1017/s0022215108003447.

Full text

Abstract:

AbstractObjectives:We report a very rare case of prostatic metastasis in the internal auditory meatus, which disappeared with treatment.Case report:An elderly man presented with a history of hearing loss, dizzy spells and, more recently, facial palsy. He also complained simultaneously of urological symptoms, which on investigation revealed advanced, metastatic prostate cancer. Radiological investigation, in the form of magnetic resonance imaging, revealed an internal auditory meatus mass which resembled an acoustic neuroma. The patient was treated with hormone injections.Tumours of the interna

APA, Harvard, Vancouver, ISO, and other styles

26

Veronesi, A., G. Lo Re, V. Dal Bo, et al. "Buserelin T reatment of Advanced Prostatic Carcinoma: Prognostic Factor Analysis." European Urology 21, no. 4 (1992): 274–79. http://dx.doi.org/10.1159/000474856.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Bosch, Ruud J. L. H., Karl H. Kurth, and Fritz H. Schroeder. "Surgical Treatment of Locally Advanced (T3) Prostatic Carcinoma: Early Results." Journal of Urology 138, no. 4 Part 1 (1987): 816–21. http://dx.doi.org/10.1016/s0022-5347(17)43383-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Sakai, Hideki, Yasuo Yogi, Yuzo Minami, Yoshiaki Yushita, Hiroshi Kanetake, and Yutaka Saito. "Prostate Specific Antigen and Prostatic Acid Phosphatase Immunoreactivity as Prognostic Indicators of Advanced Prostatic Carcinoma." Journal of Urology 149, no. 5 Part 1 (1993): 1020–23. http://dx.doi.org/10.1016/s0022-5347(17)36285-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Paulson, David F. "Management of locally advanced prostatic carcinoma by surgery: does screening for prostatic cancer make sense?" World Journal of Urology 4, no. 3 (1986): 129–35. http://dx.doi.org/10.1007/bf00327008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Rizzi, C. "Valore prognostico della ploidia cellulare nel carcinoma della prostata." Urologia Journal 62, no. 4 (1995): 565–67. http://dx.doi.org/10.1177/039156039506200409.

Full text

Abstract:

Clinical and pathological staging and histological grading do not always have sufficient value to predict the behaviour of prostatic carcinoma after prostatectomy. Many studies have suggested that DNA ploidy can provide additional prognostic information. DNA ploidy was determined by flow cytometry on paraffin-embedded tissue from 44 radical prostatectomies for carcinoma. The percentage of aneuploid tumours was higher among poorly differentiated neoplasms, in advanced stage and in cases with progression of disease, also considering the same stage and grade. DNA ploidy can represent a significan

APA, Harvard, Vancouver, ISO, and other styles

31

Çetinkaya, M., S. Günçe, E. Ulusoy, et al. "Relationship between prostate specific antigen density, microvessel density and prostatic volume in benign prostatic hyperplasia and advanced prostatic carcinoma." International Urology and Nephrology 30, no. 5 (1998): 581–85. http://dx.doi.org/10.1007/bf02550549.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Xu, Huan, Yanbo Chen, Meng Gu, et al. "Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer." Metabolites 11, no. 11 (2021): 765. http://dx.doi.org/10.3390/metabo11110765.

Full text

Abstract:

Prostate cancer (PCa) is a carcinoma in which fatty acids are abundant. Fatty acid metabolism is rewired during PCa development. Although PCa can be treated with hormone therapy, after prolonged treatment, castration-resistant prostate cancer can develop and can lead to increased mortality. Changes to fatty acid metabolism occur systemically and locally in prostate cancer patients, and understanding these changes may lead to individualized treatments, especially in advanced, castration-resistant prostate cancers. The fatty acid metabolic changes are not merely reflective of oncogenic activity,

APA, Harvard, Vancouver, ISO, and other styles

33

Anselmo, G., A. Fandella, L. Maccatrozzo, F. Merlo, P. Checchin, and M. Mangano. "Cervical or trigonal transurethral resection in locally advanced carcinoma of the prostate: What are the risks of neoplastic dissemination?" Urologia Journal 62, no. 1_suppl (1995): 129–32. http://dx.doi.org/10.1177/039156039506201s36.

Full text

Abstract:

— Patients with obstructive advanced prostatic carcinoma who do not respond to hormonal therapy need urinary drainage, usually through an indwelling catheter or nephrostomy for a dilated kidney. The authors perform an endoscopic resection of the prostate with an associated trigonal resection if there is a dilated urinary system. This kind of treatment, in successful cases, permits a better quality of life without a catheter or nephrostomies. We analysed 63 patients treated in 6 years with an average 36-month follow-up; the success of the procedure was 83% for cervical TUR and 55% for trigonal

APA, Harvard, Vancouver, ISO, and other styles

34

Minari, R., P. Salsi, and B. Monica. "Association of goserelin and flutamide in the treatment of advanced prostatic carcinoma." Urologia Journal 61, no. 2 (1994): 111–15. http://dx.doi.org/10.1177/039156039406100205.

Full text

Abstract:

From January 1987 to June 1990, 40 previously untreated patients, 60–85 years old (mean 76.7 years) with C and D stage (according to AUS) prostatic adenocarcinoma, were administered analogous LH-RH goserelin and the non-steroid antiandrogen flutamide. The patients were followed until June 1992. 9 patients died from the disease. The treatment was well tolerated in 68% of the cases (27 patients); in the other 13 patients, the administration of flutamide caused secondary effects (gastro-intestinal intolerance, alterations of hepatic function). The administration of goserelin did not cause any sec

APA, Harvard, Vancouver, ISO, and other styles

35

Kang, Minyong, Hyunwoo Lee, Sun-Ju Byeon, Ghee Young Kwon, and Seong Soo Jeon. "Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate." International Journal of Molecular Sciences 22, no. 23 (2021): 13125. http://dx.doi.org/10.3390/ijms222313125.

Full text

Abstract:

Intraductal carcinoma of the prostate (IDC-P) is a rare and unique form of aggressive prostate carcinoma, which is characterized by an expansile proliferation of malignant prostatic epithelial cells within prostatic ducts or acini and the preservation of basal cell layers around the involved glands. The vast majority of IDC-P tumors result from adjacent high-grade invasive cancer via the retrograde spreading of tumor cells into normal prostatic ducts or acini. A subset of IDC-P tumors is rarely derived from the de novo intraductal proliferation of premalignant cells. The presence of IDC-P in b

APA, Harvard, Vancouver, ISO, and other styles

36

Rahman, Mohammad Mukhlesur, Muhammad Mahmud Alam, Mohammad Ohiduzzaman Khan, Mohammad Rezaul Karim, and Md Sajid Hasan. "Frequency of Prostate Cancer Among the Prostatic Tissue Samples- Collected From Different Tertiary Level Hospital in Dhaka City." Bangladesh Journal of Urology 21, no. 2 (2020): 88–92. http://dx.doi.org/10.3329/bju.v21i2.49864.

Full text

Abstract:

Background: Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. The cancer cells may spread from the prostate to other area of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. A disease known as benign prostatic hyperplasiamay produce similar symptoms. Objective: To identify the frequency of prostate cancer in prostatic tissue submitted for histopathological examination in selected hospital of Dhaka City. Method: This analytical observational study consists of review of 3914 histopathological re

APA, Harvard, Vancouver, ISO, and other styles

37

Kennealey, Gerard T., and Barrington J. A. Furr. "Use of the Nonsteroidal Anti-androgen Casodex in Advanced Prostatic Carcinoma." Urologic Clinics of North America 18, no. 1 (1991): 99–110. http://dx.doi.org/10.1016/s0094-0143(21)01397-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Villavicencio, H. "Quality of Life of Patients with Advanced and Metastatic Prostatic Carcinoma." European Urology 24, no. 2 (1993): 118–21. http://dx.doi.org/10.1159/000474402.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

DELAERE, K. P. J., H. LELIEFELD, F. PEULEN, E. W. STAPPER, J. SMEETS, and J. WILS. "Phase II Study of Epirubicin in Advanced Hormone-resistant Prostatic Carcinoma." British Journal of Urology 70, no. 6 (1992): 641–42. http://dx.doi.org/10.1111/j.1464-410x.1992.tb15834.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Gibbs, S. J., and P. N. Plowman. "Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma." Clinical Oncology 8, no. 6 (1996): 346–52. http://dx.doi.org/10.1016/s0936-6555(96)80073-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Macbeth, F. "Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma." Clinical Oncology 9, no. 3 (1997): 197. http://dx.doi.org/10.1016/s0936-6555(97)80083-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Gonzalez-Barcena, D., P. Perez-Sanchez, S. Ureta-Sanchez, et al. "Treatment of Advanced Prostatic Carcinoma With D-Trp-6-LH-RH." Journal of Urology 134, no. 6 (1985): 1308–9. http://dx.doi.org/10.1016/s0022-5347(17)47732-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Culig, Zoran, Alfred Hobisch, Anton Hittmair, et al. "Expression, structure, and function of androgen receptor in advanced prostatic carcinoma." Prostate 35, no. 1 (1998): 63–70. http://dx.doi.org/10.1002/(sici)1097-0045(19980401)35:1<63::aid-pros9>3.0.co;2-i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Gonzalez-Barcena, David, Patricia Perez-Sanchez, Sergio Ureta-Sanchez, et al. "Treatment of advanced prostatic carcinoma with D-trp-6-LH-RH." Prostate 7, no. 1 (1985): 21–30. http://dx.doi.org/10.1002/pros.2990070104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Cerovic, Snezana, Vujadin Tatic, Jovan Dimitrijevic, et al. "Advanced prostatic carcinomas with low serum levels of prostate-specific antigen." Vojnosanitetski pregled 59, no. 2 (2002): 137–40. http://dx.doi.org/10.2298/vsp0202137c.

Full text

Abstract:

The serum levels of prostate-specific antigen (PSA) represent a significant diagnostic and monitoring parameter of prostatic carcinoma (PC). The aim of the study was to establish correlation of serum PSA level in addition to grade, histological type, and clinical stage of PC in patients with normal or intermediary PSA serum level. In 37 untreated PC patients with preoperative serum PSA levels ranging between 0.1 and 9.6 ng/ml, paraffin-embedded tissue and serum samples were immunohistological studied and immunoassay for PSA was done. The most representative was poorly differentiated PC with D

APA, Harvard, Vancouver, ISO, and other styles

46

Kuo, Chien-Chun, Su-Ya Yang, Ru-Min Liu, et al. "Diagnostic Value of Conventional Polymerase Chain Reaction for Detecting BRAF V595E Mutation in Liquid and Tissue Specimens of Canine Urothelial and Prostate Carcinomas." Animals 14, no. 17 (2024): 2535. http://dx.doi.org/10.3390/ani14172535.

Full text

Abstract:

Canine urothelial carcinoma (UC) and prostatic carcinoma (PC) often present diagnostic challenges due to their anatomical locations. The BRAF V595E mutation, analogous to the human BRAF V600E mutation, has been identified in UC and PC. Digital PCR of urine is a non-invasive diagnostic method of mutation detection, but the availability of the necessary equipment is limited. This study aimed to develop a conventional PCR to detect the BRAF V595E mutation in urine and prostatic wash specimens from dogs with UC or PC. Specific primers for detecting wild-type and mutant BRAF V595E genes were valida

APA, Harvard, Vancouver, ISO, and other styles

47

GAFFNEY, E. F., S. N. O'SULLIVAN, and A. O'BRIEN. "A major solid undifferentiated carcinoma pattern correlates with tumour progression in locally advanced prostatic carcinoma." Histopathology 21, no. 3 (1992): 249–55. http://dx.doi.org/10.1111/j.1365-2559.1992.tb00383.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Gormley, Glenn J. "Role of 5α-Reductase Inhibitors in the Treatment of Advanced Prostatic Carcinoma". Urologic Clinics of North America 18, № 1 (1991): 93–98. http://dx.doi.org/10.1016/s0094-0143(21)01396-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Johansson, Jan-Erik, and Gunnar Lingårdh. "High-Dose Medroxyprogesterone in the Treatment of Advanced Therapy-Resistant Prostatic Carcinoma." European Urology 11, no. 1 (1985): 9–10. http://dx.doi.org/10.1159/000472440.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Chodak, Gerald W. "Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma." Urology 33, no. 5 (1989): 42–44. http://dx.doi.org/10.1016/0090-4295(89)90105-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!